Kalinox 170 Bar (Nitrous Oxide, Oxygen)

Nitrous oxide acts by blocking NMDA receptors in the central nervous system and enhancing endogenous opioid pathways, which together produce analgesic and sedative effects. The oxygen component ensures sufficient oxygen delivery to support normal respiration during the procedure.

The dose of Kalinox 170 Bar is determined by the prescribing clinician based on the specific procedure, patient characteristics, and monitoring requirements. The healthcare professional adjusts the concentration and flow rate to achieve the desired level of analgesia and sedation.

The safety of nitrous oxide/oxygen inhalation in pregnancy and lactation has not been definitively established. Caution is advised, and the product should only be used if the potential benefits outweigh any possible risks, following a clinician’s assessment.

To order Kalinox 170 Bar, submit an enquiry on the product page at gnhindia.com indicating the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Kalinox 170 Bar combines nitrous oxide with oxygen, offering rapid onset of analgesia and sedation while maintaining oxygenation. Compared with pure nitrous oxide, the added oxygen reduces the risk of hypoxia. It is generally preferred over volatile anesthetic gases for brief, minimally invasive procedures due to its ease of titration and quick recovery.

Kalinox 170 Bar cylinders should be stored at ambient temperature, away from direct sunlight and heat sources. Keep them in the original packaging, secure them upright, and protect the valve from damage. Follow local regulations for compressed gas storage and handling.

Kalinox 170 Bar is administered via a calibrated inhalation system. The clinician adjusts the flow of the gas mixture to the patient’s breathing circuit, monitoring oxygen saturation and vital signs throughout the procedure to ensure safe and effective analgesia and sedation.

Serious risks include hypoxia, respiratory depression, severe hypotension, loss of consciousness, seizures, and rare allergic reactions. Continuous monitoring of respiratory and cardiovascular parameters is essential to detect and manage these events promptly.

Kalinox 170 Bar should be avoided in patients with severe chronic obstructive pulmonary disease, uncontrolled cardiovascular instability, known hypersensitivity to nitrous oxide or oxygen, and in situations where adequate scavenging cannot be ensured. Clinical judgment is required for each individual case.